论文部分内容阅读
目的：观察博宁对肺癌骨转移的止痛效果。方法：应用博宁治疗及放射治疗对照研究。结果：４０例博宁治疗组患者骨痛的止痛总有效率为８７５％，显效率达５００％。其中，单用博宁组有效率为８４６％，博宁合并放疗组有效率为９１６％，博宁合并化疗组有效率为８６７％，三组间止痛效果无显著性差异（Ｐ＞００５）。４０例单纯放射治疗的骨转移患者止痛总有效率为８２５％，显效率为３５０％。博宁应用中除少数患者出现胃肠道反应外，无明显其他毒副反应发生。结论：博宁是一种安全、有效的新一代双膦酸盐制剂，可与放疗、化疗联合应用于肺癌骨转移患者的治疗中。
Objective: To observe the analgesic effect of Bonin on bone metastasis of lung cancer. Methods: A controlled study of Bonin treatment and radiation therapy was used. RESULTS: The total effective rate of pain relief in patients with Boning treatment group was 87.5%, and the effective rate was 50.0%. Among them, the effective rate of the single-use Boning group was 84.6%, the effective rate of the Boning combined radiotherapy group was 91.6%, and the effective rate of the Bonin combined chemotherapy group was 86.7%. There was no significant difference in the analgesic effect between the three groups. (P>005). The total effective rate of pain relief in 40 patients with bone metastases treated with simple radiation was 82.5%, and the markedly effective rate was 35.0%. With the exception of a few patients with gastrointestinal reactions in Bonin, no other adverse reactions occurred. Conclusion: Bonin is a safe and effective new-generation bisphosphonate preparation that can be combined with radiotherapy and chemotherapy in the treatment of patients with bone metastases from lung cancer.